Autism & I/DD

Intellectual and developmental disabilities (I/DD) are a physical and/or cognitive impairments that occur before the age of 22. Autism spectrum disorder is generally considered a type of developmental disability that affects behaviour and communication. The autism and I/DD market provides supports and health care services to these populations. Over the past decade, there has been an increase in the changes and challenges affecting I/DD and autism markets—the move to managed care and value-based care, the shift away from residential treatment, the increasing emphasis on consumer-directed care, and new workforce challenges.

Latest Resources

• Turnover & Staffing Remain Key Concerns For I/DD Direct Support Professional Workforce
• Multiple Vail Resorts Mountain Communities Receive Combined $3.2 Million Investment For Mental Health & Substance Use Service
• Whose Evidence For Autism?
• Aetna Expands Mental Health Leadership With Dedicated Neurodiversity Support Program
• Canadian Childhood, Youth Autism Prevalence Reaches 2.25% In 2024
• Shasta Family YMCA Opens Shasta STRIDE Daily Program For Adults With Developmental Disabilities In Redding, California
• AI Autism Diagnostic Software Tool Shortened Time To Diagnosis To 39 Days
• Bristol-Myers Squibb Targets Autism Irritability With New Phase 3 Drug Trial
• IDD Navigator Platform Supports More Than 10,000 Users Since Launch
• ECM For Autism By Easterseals Southern California: An OPEN MINDS Program Profile
• Young Adults With Autism At Higher Risk Of Cardiometabolic Conditions
• Cornell University Receives $5.1 Million Grant To Fund Autism Research Center
• Evidence Base Is Weak For Complementary, Alternative & Integrative Autism Treatments, Platform Launched To Collect Additional Data
• Georgia Proposes Changes To Its HCBS Waiting List For Those With I/DD
• Whose Evidence?

See All

HHS Announces Actions To Address Rising Autism Prevalence

At a September 22 press event, President Donald J. Trump and U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy, Jr. announced actions to address what an accompanying press release described as an “autism spectrum disorder (ASD) epidemic.” Actions include a U.S. Food and Drug Administration (FDA) label update for leucovorin for cerebral folate deficiency, authorizing treatment for children with ASD and enabling state Medicaid programs to cover leucovorin for the indication… Read

• Georgia Department Of Behavioral Health & Developmental Disabilities Board Meeting December 18, 2025 Presentation
• Best Practices To Integrate Your Systems Of Care: A Conversation With Srinivas Velamoor, President & CEO Of NextGen Healthcare
• Virginia Reports Three-Year Outcomes Of Behavioral Health Transformation To Expand Access, Strengthen Support For Individuals & Families
• DOJ Moves To End 16-Year Texas Civil Rights Case Against 13 State-Supported Living Centers For People With I/DD
• New Story Schools Opening New Campus In Berea, Ohio, In January 2026

To sign-up for monthly Autism & I/DD Services alerts, you must be signed in to your account.